Public-health topic
Published Research Radar records connected to the Vaccine effectiveness topic through the auditable classification pipeline.
Evidence stream
30 of 120 publications shown
Vaccine
Why it matters nowThese aggregated results guide international immunization planning and highlight structural improvements needed for future outbreak responses, such as unified research methodologies and integrated health databases.
Vaccine
Why it matters nowFindings support continued COVID-19 vaccine recommendations, demonstrating protection across the 2024-2025 season for adults including those with underlying medical conditions.
Tropical Medicine and Infectious Disease
Why it matters nowThe article frames precision vaccinology as relevant to mpox preparedness and development of vaccines intended to provide durable, clade-specific protection. The supplied abstract does not provide clinical effectiveness estimates or outcome data supporting a specific public health intervention.
Vaccine
Why it matters nowThe findings suggest that routine one-dose MCV delivery alone is insufficient to reach the measles population-immunity threshold under the model's central assumptions, and that sustained two-dose routine immunisation, high-reach SIAs, and restored immunisation-system capacity may be required.
Vaccines
Why it matters nowThe authors frame the findings as relevant to vaccination policy, arguing that controlling for healthy-vaccinee bias is important when comparing vaccine effectiveness and that, during a period of high vaccine availability and COVID-19 mortality, Moderna was associated with lower COVID-19 mortality than Pfizer. A higher Moderna dose is suggested as a possible explanation.
Frontiers in Public Health
Why it matters nowFindings support self-collected nasal swabs as a feasible surveillance option that may enable earlier sampling and higher pathogen detection, particularly when collected within 7 days of symptom onset.
Vaccines
Why it matters nowSeasonal influenza vaccination provided substantial protection against severe respiratory outcomes in a high-risk population with COPD, supporting vaccination as a public health intervention in this group.
npj Vaccines
Why it matters nowThe reported durability and breadth of the cellular response suggest a potential strategy to overcome the immune evasion and waning protection associated with current spike-focused immunizations.
Influenza and Other Respiratory Viruses
Why it matters nowThe findings indicate that seasonal influenza vaccination provided meaningful protection against hospitalisation in 2024/25, with the largest benefit observed in children, supporting continued vaccination efforts in Northern Ireland.
Vaccine
Why it matters nowThe discussion is relevant to accelerating ethically acceptable evaluation of Nipah and other outbreak vaccines, including the role of early and sustained community engagement across epidemic and inter-epidemic periods.
Vaccine
Why it matters nowThe synthesized data supply real-world effectiveness metrics that inform health policy regarding vaccine deployment across varied clinical risk categories and aging populations.
Vaccine
Why it matters nowPersistent malaria transmission may erode long-term humoral immunity to pertussis following natural infection, with potential implications for pertussis control strategies and booster vaccination scheduling in malaria-endemic regions.
Vaccine
Why it matters nowThe modeling results suggest that integrating adult demographics into future immunization campaigns could optimize resource allocation and disease reduction in highly affected regions. Policymakers might consider these economic parameters when planning next-generation preventive tools against this parasitic infection.
Vaccine
Why it matters nowThe adaptable architecture of this delivery mechanism supports future development of combined immunizations targeting multiple vivax malaria components, aligning with broader disease control objectives.
Vaccine
Why it matters nowScaling up advanced immunization protocols for senior citizens may reduce seasonal disease burden and alleviate pressure on medical facilities during peak viral circulation periods.
Vaccine
Why it matters nowThese outcomes reinforce the utility of existing immunization protocols for youth amid evolving viral genetics, highlighting the need for longitudinal tracking as alternative delivery methods gain traction.
The Lancet Infectious Diseases
Why it matters nowThe findings could inform immunological evaluation of RTS,S/AS01E by identifying antibody durability and maintenance, rather than peak responses alone, as potentially relevant correlates of vaccine efficacy.
Vaccine
Why it matters nowWaning immunity following acellular pertussis vaccination has been observed in pertussis outbreaks, creating a need for more effective acellular pertussis vaccines. The findings support the potential use of this 2-component vaccine as a pertussis booster in adults.
Vaccine
Why it matters nowThe research addresses ongoing challenges in seasonal influenza prevention by exploring an alternative manufacturing approach that may broaden cross-strain coverage. While promising for future therapeutic pipelines, the results remain confined to animal models and require further validation before public health implementation.
Vaccine
Why it matters nowThe findings demonstrate that KP.2 vaccine provides meaningful but short-lived protection against COVID-19 hospitalization in older adults, informing vaccination timing and booster strategies for this vulnerable population.
International Journal of Infectious Diseases
Why it matters nowMonkeypox infection and smallpox vaccination may provide cross-protection against orthopoxviruses. Early IgA detection could support mpox diagnosis in asymptomatic high-risk individuals, and complement-dependent neutralization assays may improve cross-immunity assessment.
Vaccine
Why it matters nowThe findings provide comparative context for interpreting seasonal influenza vaccine-effectiveness estimates across periods and age groups. The abstract indicates that factors other than population immunity could account for the observed differences, so the results do not establish a single explanation.
Vaccine
Why it matters nowThe abstract identifies increased use of the two-dose schedule, evaluation of the vaccination interval, and possible inclusion of varicella vaccine in national programs as measures that could reduce breakthrough infections. These implications are the authors' conclusions and are not independently validated by the supplied evidence.
Vaccine
Why it matters nowThe findings suggest mRNA-1345 provides substantial real-world protection against RSV-related hospitalization and healthcare utilization in older adults, supporting the vaccine's value for reducing RSV disease burden in high-risk populations.
Vaccine
Why it matters nowThe findings provide experimental evidence that Likh1-/- may warrant further investigation as an immunoprophylactic approach for visceral leishmaniasis. The supplied evidence is limited to an animal model and does not establish effectiveness, safety, or feasibility in humans.
Vaccine
Why it matters nowThe findings provide context on observed hospitalization and mortality patterns among laboratory-confirmed Omicron cases according to documented prior immunity profiles in this Iranian registry population. The analysis does not estimate protection against acquiring infection.
Journal of Travel Medicine
Why it matters nowInconsistent international protocols complicate clinical counseling and traveler preparedness for dengue-endemic destinations. Harmonizing future advisories will likely depend on supplementary effectiveness data targeting specific demographic groups currently underrepresented in clinical trials. Maintaining transparent dialogue between providers and patients remains critical amid these policy discrepancies.
Clinical Infectious Diseases
Why it matters nowThe study provides a U.S. outpatient VE estimate for the 2024–2025 season, indicating vaccination reduced the risk of outpatient medically attended influenza by roughly one-third despite the predominance of A(H1N1)pdm09 and A(H3N2) viruses.
npj Vaccines
Why it matters nowSuccessful stabilization and scalable preparation of this candidate could streamline the transition from laboratory research to regulated clinical testing for filarial disease prevention.
BMC Infectious Diseases
Why it matters nowThe findings address vaccine-preventable PCC burden in a high-risk age group during the first post-pandemic season and are positioned as input for vaccination policy, communication, and clinical decision-making.
